TLDR:
- Symbiotic Capital, a new global life science credit firm, has raised over $600 million to provide credit solutions to companies in the healthcare sector.
- Associated with Bellco Capital, the firm aims to help life science companies fund ongoing R&D, capital expenses, and commercialization activities without equity demands.
A new global life science credit firm called Symbiotic Capital has recently been unveiled with over $600 million in funding. The California-based firm, associated with Bellco Capital, aims to deliver credit solutions to companies in the biotech, medtech, synthetic biology, and other healthcare sectors. Led by Arie Belldegrun, M.D., Symbiotic Capital’s co-chair, the firm aims to support the increasing capital needs of healthcare companies by offering credit without the equity demands that traditional financing institutions require.
According to Belldegrun, the life science industry is experiencing unprecedented productivity, innovation, and scientific discovery, making credit an essential financing tool for established healthcare enterprises. Symbiotic Capital’s credit financings are designed to help companies fund ongoing research and development, capital expenses, and commercialization activities. Former Roche CEO Franz Humer, Ph.D., and former Cleveland Clinic CEO Toby Cosgrove, M.D., have joined the firm’s science team to support its mission.
Symbiotic Capital has been designed as a science-first credit platform to support the convergence of biotechnology and technology in the healthcare sector. The firm’s focus on providing credit solutions to companies in need of financing for their innovative therapeutics, devices, tools, and other products sets it apart in the competitive financing environment of the life science industry.
